2 terminated, 1 completed. 3 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Terminated 2, Completed 1 |
| Phase 3 | 1 | Terminated 1 |
Follow anagrelide: new trials by email Literature Review of anagrelide trials Research Report on anagrelide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272) Ruxolitinib, Anagrelide, Placebo - MPN (Myeloproliferative Neoplasms) | Phase 2 | Terminated | Incyte Corporation | 12 | 2017-11-14 | 2021-11-19 |
| The Ruxolitinib Versus Best Available Therapy Trial in Patients With High Risk ET in Second Line Anagrelide, Ruxolitinib (JAKAVI®), IFNα/ PegIFNα - Essential Thrombocythemia | Phase 2 / Phase 3 | Terminated | French Innovative Leukemia Organisation | 13 | 2017-01-03 | 2021-06-29 |
| The Pharmacokinetics of Anagrelide in Elderly and Young Patients With Essential Thrombocythaemia (ET) anagrelide hydrochloride - Essential Thrombocythaemia | Phase 2 | Completed | Shire | 24 | 2006-11-13 | 2021-06-29 |
Thrombocythemia, Essential (3) · Myeloproliferative Disorders (1)
French Innovative Leukemia Organisation (1) · Incyte Corporation (1) · Shire (1)
France (1) · Spain (1) · Sweden (1) · United Kingdom (1) · United States (1)
Albert Assad, MD (1)
2004 (1)